D. Sheinson

发表

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

R. Bourgon, P. Hegde, Yulei N. Wang, 2018, Nature.

Comparison of the performance of particle filter algorithms applied to tracking of a disease epidemic.

W. Meiring, Jarad Niemi, D. Sheinson, 2014, Mathematical biosciences.

The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder

D. Sheinson, M. Yeaman, A. Exuzides, 2021, Journal of the Neurological Sciences.

A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States

D. Sheinson, S. Kowal, J. Dang, 2021, Advances in Therapy.

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis

G. Pardo, D. Sheinson, Carmen D. Ng, 2022, Journal of health economics and outcomes research.

Reply to Hunsberger and Memoli, “Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat”

Rob Lambkin-Williams, Haiyin Chen-Harris, C. Rosenberger, 2017, Antimicrobial Agents and Chemotherapy.

In vitro assessment of chemotherapy-induced neuronal toxicity.

D. Sheinson, D. Misner, T. Ngo, 2018, Toxicology in vitro : an international journal published in association with BIBRA.

Rapid Development of Glaucoma Via ITV Nonselective ANGPT 1/2 Antibody: A Potential Role for ANGPT/TIE2 Signaling in Primate Aqueous Humor Outflow.

J. Ridgway, Minhong Yan, G. Fuh, 2019, Investigative ophthalmology & visual science.

The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis

D. Sheinson, R. Cookson, S. Kowal, 2022, Value in Health.

Sequential Monte Carlo methods: applications to disease surveillance and fMRI data

Daniel Sheinson, D. Sheinson, 2014 .

Variance component analysis of circulating miR-122 in serum from healthy human volunteers

J. Vogt, D. Sheinson, W. Proctor, 2019, PloS one.

Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination

D. Sheinson, M. Fleury, C. Meyer, 2021, JAMA network open.

Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing

C. Gross, D. Sheinson, S. Ogale, 2021, JCO oncology practice.

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients

D. Snydman, N. Lewin-Koh, D. Sheinson, 2019, Open forum infectious diseases.

Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.

A. Mansfield, D. Sheinson, W. Wong, 2020, Lung cancer.

HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age

D. Sheinson, J. Sussell, B. Shah-Manek, 2020, Advances in Therapy.

Five-Year Patterns of Diabetic Retinopathy Progression in US Clinical Practice

I. Abbass, A. Moshfeghi, D. Sheinson, 2020, Clinical Ophthalmology.

Estimated Impact of Public and Private Sector COVID-19 Diagnostics and Treatments on US Healthcare Resource Utilization

D. Sheinson, W. Wong, Anuj M. Shah, 2020, Advances in Therapy.

Impact of public and private sector COVID-19 diagnostics and treatments on US healthcare resource utilization

D. Sheinson, W. Wong, A. Shah, 2020, medRxiv.

Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model

Rob Lambkin-Williams, Haiyin Chen-Harris, C. Rosenberger, 2017, Antimicrobial Agents and Chemotherapy.

In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection.

D. Sheinson, W. Halpern, A. Nguyen, 2019, Toxicological sciences : an official journal of the Society of Toxicology.

Costs associated with the use of multigene panel tests in three solid tumor types and the impact on insurance premiums.

D. Sheinson, W. Wong, T. To, 2023, Future oncology.

Healthcare Resource Use and Burden Associated with Influenza Transmission Among Household Members with a Primary Infection: Commercial Claims Data Analysis

I. Abbass, D. Sheinson, C. Wallick, 2021, ClinicoEconomics and outcomes research : CEOR.

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis

G. Pardo, D. Sheinson, Carmen D. Ng, 2022, Neurology and Therapy.

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data

G. Pardo, D. Sheinson, Carmen D. Ng, 2021, Journal of managed care & specialty pharmacy.

Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder

D. Sheinson, M. Yeaman, A. Exuzides, 2021, Journal of the Neurological Sciences.

Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database

D. Sheinson, A. Exuzides, P. Sidiropoulos, 2021, Journal of medical economics.

Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer

M. Secrest, D. Sheinson, K. Sarsour, 2022, The oncologist.

Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab

D. Sheinson, Caroline K. Geiger, T. To, 2023, Neurology and Therapy.

The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization.

C. Gross, D. Sheinson, S. Ogale, 2020 .